Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 3/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.69 |
| ▸ | PPARG | P37231 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | FABP4 | P15090 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479725 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL12970667 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL6382220 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1479722 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1476445 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL16670813 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL15902619 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL22607964 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL21214020 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL198434 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120326025-A1 | DIAGNOSING PROSTATE CANCER RELAPSE | IMG Institut fur Medizinische Genomforschung Planu ngsgesellschaft (AT) | 2012-12-27 | — | — | US | claimed |
| EP-2354794-A1 | Diagnosing prostate cancer relapse | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. (AT) | 2011-08-10 | — | — | EP | claimed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| CN-120870371-A | Application of marker metabolite in identifying different harvest periods of porphyra haitanensis | 集美大学 | 2025-10-31 | — | — | CN | disclosed |
| US-20250231204-A1 | EXHALED BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF PATIENT WITH IDIOPATHIC PULMONARY FIBROSIS | UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) | 2025-07-17 | — | — | US | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250051763-A1 | METHODS AND SYSTEMS FOR CONDITIONALLY REGULATING GENE EXPRESSION | FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2025-02-13 | — | — | US | disclosed |
| CN-118818068-A | Application of urine arachidonic acid and metabolite thereof in GDM diagnosis and prediction in early pregnancy | 上海市生物医药技术研究院 | 2024-10-22 | — | — | CN | disclosed |
| US-20240084335-A1 | CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2024039205-A1 | EXHALED BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF PATIENT WITH IDIOPATHIC PULMONARY FIBROSIS | 울산대학교 산학협력단 | 2024-02-22 | — | — | WO | disclosed |
| US-20240044871-A1 | CHIMERIC RECEPTOR POLYPEPTIDE AND METHODS OF ACTIVATION THEREOF | FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2024-02-08 | — | — | US | disclosed |
| US-20120326025-A1 | DIAGNOSING PROSTATE CANCER RELAPSE | IMG Institut fur Medizinische Genomforschung Planu ngsgesellschaft (AT) | 2012-12-27 | — | — | US | disclosed |
| US-20120326025-A1 | DIAGNOSING PROSTATE CANCER RELAPSE | IMG Institut fur Medizinische Genomforschung Planu ngsgesellschaft (AT) | 2012-12-27 | — | — | US | disclosed |
| US-20120202240-A1 | Method for Predicting the likelihood of an Onset of an Inflammation Associated Organ Failure | BIOCRATES LIFE SCIENCES AG | 2012-08-09 | — | — | US | disclosed |
| EP-2460014-A1 | METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE | BIOCRATES Life Sciences AG (AT) | 2012-06-06 | — | — | EP | disclosed |
| US-20120129265-A1 | NEW BIOMARKERS FOR ASSESSING KIDNEY DISEASES | BIOCRATES LIFE SCIENCES AG (AT) | 2012-05-24 | — | — | US | disclosed |
| EP-2354794-A1 | Diagnosing prostate cancer relapse | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. (AT) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354794-A1 | Diagnosing prostate cancer relapse | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. (AT) | 2011-08-10 | — | — | EP | disclosed |
| WO-2011012553-A1 | METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE | BIOCRATES LIFE SCIENCES AG (AT) | 2011-02-03 | — | — | WO | disclosed |
| US-5725804-A | ALBUMIN PARTICLES STABLE TO RESOLUBILIZATION, POLYOXYETHYLENE GLYCOL, ALCOHOL | HEMOSPHERE, INC. (US) | 1998-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | OXER1 3091/4885LTB4R2 3626/4885MAPT 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.